CDNACareDx, Inc.
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~13% a year FCF growth. Roughly in line with its three-year revenue growth of 14% a year.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CDNA's price assumes
CareDx, Inc. trades at 30.8× earnings against 35.2× for the median Diagnostics & Research name, cheaper than its own group.
Trailing P/E · Diagnostics & Research median 35.2 · cheaper than the typical name in its group
- Price / sales
- 3.79
Price / sales · today's price, fiscal year to Dec 31, 2025
- Free cash flow yield
- 2.8%
Free cash flow yield · Diagnostics & Research median 3.7%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; revenue has grown +14% a year over the last three.
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 4.75
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 3.32
- Healthcare median P/E509 names
- 26.2
- Diagnostics & Research median P/E33 names
- 35.2
- Free cash flow, trailing twelve months
- $41M
- Market capitalisation
- $1.44B
- 3-year revenue growth
- +14%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #5 of 21 by RyuScore